Target
BCL2
17 abstracts
Abstract
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Org: Lymphoma and Myeloma Research Amsterdam, St. James's Hospital, BeiGene International GmbH, Department of Haematological Medicine,
Abstract
Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings.Org: St. Luke's Roosevelt,
Abstract
Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis.Org: a Dassault Systèmes Company,
Abstract
BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.Org: Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Hattiesburg Clinic, Genesis Care North Shore, Affiliated Zhongshan Hospital of Fudan University, BeiGene (Beijing) Co, Ltd,
Abstract
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).Org: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, Namık Kemal Üniversitesi, Nantes University Hospital, Centre Hospitalier Universitaire (CHU) de Poitiers,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.Org: Alexandra Hospital - University of Athens, Medical School, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Würzburg University Hospital, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,
Abstract
Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Abstract
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).Org: Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau, Nimes, France, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France, Seoul National University Hospital, Seoul, Korea, Republic of (South),
Abstract
The characteristics of metabolic related pathways under different anoikis activities revealed by pan-cancer analyses.Org: Hangzhou Repugene Technology Co., Ltd., Hangzhou Repugene Technology Co,.Ltd,
Abstract
Efficacy of COVID vaccinations in patients with chronic lymphocytic leukemia.Org: The Ohio State University - James Cancer Hospital, UT Southwestern Medical Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital,
Abstract
Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.Org: Medical College of Wisconsin, Actinium Pharmaceuticals,
Abstract
Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer.Org: Invitrocue Europe AG, Invitrocue Hong Kong Ltd, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Technical University of Munich (TUM), Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China,
Abstract
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,